Compare Cognizant Technology Solutions Corp (CTSH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Twist Bioscience Corp — how do they compare? Cognizant Technology Solutions Corp trades at $60.2 (market cap $27.03B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Cognizant Technology Solutions Corp is far larger — about 2.7× Twist Bioscience Corp's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Twist Bioscience Corp for 27 Days on average.
| CTSH | TWST | |
|---|---|---|
Market Cap | $27.03B | $10.08B |
Volume | 9,883,888 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $86.70 | $205.00 |
52-Week Low | $38.73 | $25.45 |
Typical Hold Time | 57 Days | 27 Days |
Enterprise Value | $28.08B | $10.01B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% on the day, with a bearish technical signal from moving averages. The company reported revenue of $21.11B in 2025 with a net income margin of 10.26%, and recent quarterly earnings have mostly beaten expectations. Analysts maintain a consensus price target of $64.25, with 45.1% recommending a buy. Positive news includes AI partnerships and workplace recognitions, but cash flow trends show volatility.
CTSH presents a mixed outlook: undervalued fundamentals with a P/E of 12.88 and strong profitability support upside potential, but technical weakness and competitive IT spending pressures pose risks. The stock's performance hinges on Q3 2026 earnings results due October 29, 2026, which could validate AI-driven growth initiatives or exacerbate bearish sentiment.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
